Business
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2026 on Wednesday, May 27, 2026, before the U.S. markets open.
About this update from Biolinerx Ltd.
[{"type":"text","content":"Management to Hold Conference Call at 8:30 a.m. EDT","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2026 on Wednesday, May 27, 2026, before the U.S. markets open.","length":361,"tagName":"p"},{"type":"image","alt":"BioLineRx Ltd Logo","displaySize":"","headline":null,"caption":"BioLineRx Ltd Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I2d.qLr3NvmwANgRGS5CpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OQ--/https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a","width":400,"height":107},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/9F8ulJEpu4haRkfOhwex2g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE3MQ--/https://media.zenfs.com/en/prnewswire.com/b069ac9f15d655849a2707e7c3811a1a","width":400,"height":107}}},{"type":"text","content":"The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.","length":117,"tagName":"p"},{"type":"text","content":"To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 28, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.","length":593,"tagName":"p"},{"type":"text","content":"About BioLineRx","length":15,"tagName":"p"},{"type":"text","content":"BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, s...